How One Rogue Scientist Could Sink Global Gene Therapy Progress
Amid a global uproar denouncing a Chinese scientist’s work to deliver gene-edited twin babies, worries emerge that other valuable future research in the area could be put on hold, effectively crippling industry experts and researchers.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
Consolidated Appropriations Act gives FDA $5.58bn overall, 8.7% more than allocated in FY 2018. FDA received $268.8m in additional budget authority and $178.3m in additional user fee funds. FY 2019 funding would have lapsed Feb. 16 and another government shutdown would have started if President Trump didn't sign the bill on Feb. 15.